Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.26
NVS's Cash-to-Debt is ranked lower than
80% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. NVS: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
NVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.19 Max: N/A
Current: 0.26
Equity-to-Asset 0.51
NVS's Equity-to-Asset is ranked lower than
68% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVS: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
NVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.51
0.51
0.65
Interest Coverage 10.99
NVS's Interest Coverage is ranked lower than
72% of the 638 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.48 vs. NVS: 10.99 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 10.99  Med: 16.22 Max: 30.91
Current: 10.99
10.99
30.91
Piotroski F-Score: 7
Altman Z-Score: 2.41
Beneish M-Score: -2.76
WACC vs ROIC
6.05%
7.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 15.62
NVS's Operating Margin % is ranked higher than
71% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. NVS: 15.62 )
Ranked among companies with meaningful Operating Margin % only.
NVS' s Operating Margin % Range Over the Past 10 Years
Min: 15.62  Med: 20.76 Max: 22.35
Current: 15.62
15.62
22.35
Net Margin % 12.83
NVS's Net Margin % is ranked higher than
72% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. NVS: 12.83 )
Ranked among companies with meaningful Net Margin % only.
NVS' s Net Margin % Range Over the Past 10 Years
Min: 12.83  Med: 18.81 Max: 35.29
Current: 12.83
12.83
35.29
ROE % 8.78
NVS's ROE % is ranked higher than
56% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NVS: 8.78 )
Ranked among companies with meaningful ROE % only.
NVS' s ROE % Range Over the Past 10 Years
Min: 8.78  Med: 14.79 Max: 25.73
Current: 8.78
8.78
25.73
ROA % 4.81
NVS's ROA % is ranked higher than
56% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NVS: 4.81 )
Ranked among companies with meaningful ROA % only.
NVS' s ROA % Range Over the Past 10 Years
Min: 4.81  Med: 8.59 Max: 16.19
Current: 4.81
4.81
16.19
ROC (Joel Greenblatt) % 47.05
NVS's ROC (Joel Greenblatt) % is ranked higher than
82% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.07 vs. NVS: 47.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.78  Med: 59.62 Max: 69.75
Current: 47.05
43.78
69.75
3-Year Revenue Growth Rate 2.90
NVS's 3-Year Revenue Growth Rate is ranked lower than
58% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NVS: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.9  Med: 2.5 Max: 12.3
Current: 2.9
-3.9
12.3
3-Year EBITDA Growth Rate -4.80
NVS's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 0.4 Max: 11.6
Current: -4.8
-7.7
11.6
3-Year EPS without NRI Growth Rate -4.80
NVS's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 3.2 Max: 82
Current: -4.8
-7.1
82
GuruFocus has detected 6 Warning Signs with Novartis AG $NVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVS's 30-Y Financials

Financials (Next Earnings Date: 2017-07-18)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:PFE, OTCPK:RHHBY, NYSE:MRK, NYSE:SNY, NYSE:ABBV, OTCPK:BAYZF, OTCPK:GLAXF, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHF, NAS:HCM » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Headquarter Location:Switzerland
Novartis AG is in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals. Its portfolio includes pharmaceuticals and oncology medicines, generic and biosimilar medicines and eye care devices.

Novartis develops and manufactures health-care products in four main operating segments: branded drugs, generic pharmaceuticals, eye care products, and consumer products. The company sells its products globally with the U.S. representing close to a third of total sales.

Guru Investment Theses on Novartis AG

Jerome Dodson Comments on Novartis - Apr 26, 2017

With the market at all-time highs, it’s difficult to find undervalued stocks with attractive prospects. However, we uncovered a few that we believe are hidden gems. Our first new addition is Novartis (NYSE:NVS), the Swiss pharmaceutical giant. Management is focused on turning around Alcon, its leading eye-care franchise, whose sales have been soft the past few years. We recently met with Mike Ball, the CEO of Alcon, and we’re impressed with his vision to reinvigorate this great business. Meanwhile, investors are giving the company little credit for its enviable portfolio of innovative therapies that should drive revenue growth, including Entresto, an exciting new treatment that provides hope for chronic heart failure patients.

Jerome Dodson (Trades, Portfolio)'s first quarter 2017 Parnassus Funds commentary.

Check out Jerome Dodson latest stock trades

Top Ranked Articles about Novartis AG

DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP The guru's largest 1st-quarter transactions
Dodge & Cox was founded in 1930 by Van Duyn Dodge and E. Morris Cox, and it manages a portfolio of 179 stocks. During the first quarter the guru traded shares in the following companies. Read more...
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
Novartis Releases 1st-Quarter Earnings The Swiss company reported a solid quarter with a substantial increase in cash flow
Novartis AG (NYSE:NVSreleased its first-quarter 2017 financial results on April 25.  Read more...
Jerome Dodson Comments on Novartis Guru stock highlight
With the market at all-time highs, it’s difficult to find undervalued stocks with attractive prospects. However, we uncovered a few that we believe are hidden gems. Our first new addition is Novartis (NYSE:NVS), the Swiss pharmaceutical giant. Management is focused on turning around Alcon, its leading eye-care franchise, whose sales have been soft the past few years. We recently met with Mike Ball, the CEO of Alcon, and we’re impressed with his vision to reinvigorate this great business. Meanwhile, investors are giving the company little credit for its enviable portfolio of innovative therapies that should drive revenue growth, including Entresto, an exciting new treatment that provides hope for chronic heart failure patients. Read more...
Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter Guru invests in IT and pharmaceutical companies
Jerome Dodson (Trades, Portfolio)’s Parnassus Fund established two new positions and sold out of two others in the first quarter of the year. He bought Cognizant Technology Solutions Corp. (NASDAQ:CTSH) and Novartis AG (NYSE:NVS). He sold Qualcomm Inc. (NASDAQ:QCOM) and Applied Materials Inc. (NASDAQ:AMAT). Read more...
Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth A low-risk dividend for the short to mid term
From the price to sales point of view, Merck (NYSE:MRK) is one of the most expensive healthcare stocks, trading at nearly 4.5 times sales, more than you need to pay for Pfizer (NYSE:PFE) or Novartis (NYSE:NVS). Merck is possibly the only pharma major to see its stock price almost steadily rise in the last five years. It has more than doubled its price during that time, from under $30 in August 2011 to above $60 in August 2016. Read more...

Ratios

vs
industry
vs
history
PE Ratio 31.54
NVS's PE Ratio is ranked lower than
58% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.96 vs. NVS: 31.54 )
Ranked among companies with meaningful PE Ratio only.
NVS' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.96 Max: 31.95
Current: 31.54
5.7
31.95
Forward PE Ratio 17.89
NVS's Forward PE Ratio is ranked higher than
57% of the 68 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.46 vs. NVS: 17.89 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.54
NVS's PE Ratio without NRI is ranked lower than
58% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.64 vs. NVS: 31.54 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.24 Max: 31.95
Current: 31.54
10.63
31.95
Price-to-Owner-Earnings 20.96
NVS's Price-to-Owner-Earnings is ranked higher than
69% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. NVS: 20.96 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 15.41 Max: 21.91
Current: 20.96
7.18
21.91
PB Ratio 2.90
NVS's PB Ratio is ranked higher than
50% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. NVS: 2.90 )
Ranked among companies with meaningful PB Ratio only.
NVS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.44 Max: 3.74
Current: 2.9
1.69
3.74
PS Ratio 4.03
NVS's PS Ratio is ranked lower than
60% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. NVS: 4.03 )
Ranked among companies with meaningful PS Ratio only.
NVS' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.27 Max: 5.03
Current: 4.03
1.89
5.03
Price-to-Free-Cash-Flow 21.97
NVS's Price-to-Free-Cash-Flow is ranked higher than
58% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.35 vs. NVS: 21.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.04  Med: 17.23 Max: 26.65
Current: 21.97
7.04
26.65
Price-to-Operating-Cash-Flow 16.71
NVS's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.13 vs. NVS: 16.71 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 13.25 Max: 19.28
Current: 16.71
5.75
19.28
EV-to-EBIT 27.27
NVS's EV-to-EBIT is ranked lower than
66% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.48 vs. NVS: 27.27 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 27.9
Current: 27.27
8.5
27.9
EV-to-EBITDA 17.23
NVS's EV-to-EBITDA is ranked higher than
51% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.55 vs. NVS: 17.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18.1
Current: 17.23
7.3
18.1
Shiller PE Ratio 17.16
NVS's Shiller PE Ratio is ranked higher than
85% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.91 vs. NVS: 17.16 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.73  Med: 14.87 Max: 21.43
Current: 17.16
9.73
21.43
Current Ratio 0.98
NVS's Current Ratio is ranked lower than
89% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. NVS: 0.98 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.35 Max: 2.83
Current: 0.98
0.83
2.83
Quick Ratio 0.73
NVS's Quick Ratio is ranked lower than
88% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. NVS: 0.73 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.08 Max: 2.48
Current: 0.73
0.59
2.48
Days Inventory 137.66
NVS's Days Inventory is ranked lower than
60% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. NVS: 137.66 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 137.66
117.82
183.45
Days Sales Outstanding 61.48
NVS's Days Sales Outstanding is ranked higher than
63% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. NVS: 61.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 61.48
56.31
70.59
Days Payable 96.74
NVS's Days Payable is ranked higher than
67% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. NVS: 96.74 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 96.74
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.19
NVS's Dividend Yield % is ranked higher than
91% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. NVS: 3.19 )
Ranked among companies with meaningful Dividend Yield % only.
NVS' s Dividend Yield % Range Over the Past 10 Years
Min: 1.49  Med: 3.43 Max: 5.11
Current: 3.19
1.49
5.11
Dividend Payout Ratio 1.02
NVS's Dividend Payout Ratio is ranked lower than
91% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. NVS: 1.02 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 1.02
Current: 1.02
0.4
1.02
3-Year Dividend Growth Rate 7.60
NVS's 3-Year Dividend Growth Rate is ranked higher than
51% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. NVS: 7.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -70.6  Med: 7.85 Max: 18.5
Current: 7.6
-70.6
18.5
Forward Dividend Yield % 3.19
NVS's Forward Dividend Yield % is ranked higher than
81% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.71 vs. NVS: 3.19 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.12
NVS's 5-Year Yield-on-Cost % is ranked higher than
86% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. NVS: 4.12 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.92  Med: 4.42 Max: 6.58
Current: 4.12
1.92
6.58
3-Year Average Share Buyback Ratio 0.70
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. NVS: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 40.21
NVS's Price-to-Tangible-Book is ranked lower than
96% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. NVS: 40.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 4.41 Max: 12455
Current: 40.21
2.68
12455
Price-to-Intrinsic-Value-Projected-FCF 1.37
NVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. NVS: 1.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.67  Med: 1.15 Max: 2.52
Current: 1.37
0.67
2.52
Price-to-Median-PS-Value 1.24
NVS's Price-to-Median-PS-Value is ranked lower than
62% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. NVS: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.14 Max: 3.1
Current: 1.24
0.64
3.1
Price-to-Graham-Number 7.50
NVS's Price-to-Graham-Number is ranked lower than
93% of the 484 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. NVS: 7.50 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 2.05 Max: 81.67
Current: 7.5
1.27
81.67
Earnings Yield (Greenblatt) % 3.68
NVS's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. NVS: 3.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.6  Med: 6.4 Max: 11.8
Current: 3.68
3.6
11.8
Forward Rate of Return (Yacktman) % 3.22
NVS's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. NVS: 3.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 13.2 Max: 56.6
Current: 3.22
1
56.6

More Statistics

Revenue (TTM) (Mil) $49,411.00
EPS (TTM) $ 2.66
Beta0.72
Short Percentage of Float0.00%
52-Week Range $66.93 - 86.90
Shares Outstanding (Mil)2,365.60 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,136 51,287 54,692
EPS ($) 4.73 5.16 5.77
EPS without NRI ($) 4.73 5.16 5.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.10%
Dividends per Share ($) 2.80 2.95 3.18
» More Articles for NVS

Headlines

Articles On GuruFocus.com
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective Jun 19 2017 
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Jun 07 2017 
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP May 25 2017 
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR May 08 2017 
Jerome Dodson Comments on Novartis Apr 26 2017 
Novartis Releases 1st-Quarter Earnings Apr 26 2017 
Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter Apr 17 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Novartis Has Bright Future Feb 01 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 

More From Other Websites
Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe Jun 28 2017
Invest in these European underperformers now before Daniel Loeb does Jun 28 2017
Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race? Jun 27 2017
Novartis gets European OK for biosimilar of Amgen's Enbrel Jun 27 2017
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk Jun 26 2017
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved Jun 26 2017
Better Buy: Exelixis, Inc. vs. Novartis AG Jun 24 2017
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod Jun 23 2017
Novartis breast cancer drug Kisqali wins European panel backing Jun 23 2017
Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day Jun 22 2017
Novartis Pops To 5-Month High On Strong Trial In Heart Attack Survivors Jun 22 2017
Drugmakers May Lose $390B In Sales Over 5 Years Jun 22 2017
Novartis' CANTOS Heart Trial Results Could Lead To Drastic Drop In Arthritis Drug Price Jun 22 2017
Health stocks help European equities cut losses Jun 22 2017
Healthcare Leads as Stocks Turn Higher After Release of Senate Bill Jun 22 2017
Novartis Announces Positive Results for Cardiovascular Drug Jun 22 2017
Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide Jun 22 2017
Novartis Drug Becomes First To Prevent Heart Attacks And Strokes By Targeting Inflammation Jun 22 2017
Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success Jun 22 2017
Novartis Migraine Drug Accepted, AMD Positive in Phase III Jun 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}